Each ml of the solution contains : 10000 anti-Xa IU equivalent to 100mg Enoxaparin sodium. Cardinex-40 : 4000 anti-Xa IU/0.4ml.
Cardinex is indicated for o Prophylaxis of venous thromboembolic disease (prevention of blood clot formation in the veins). Prevention of thrombus formation in the extracorporal circluation during haemodialysis.Treatment of unstable angina and non-Q-wave myocardial infarction during acute stage.Treatment of established deep vein thrombosis with or without pulmonary embolism.
Each ml of the solution contains : 10000 anti-Xa IU equivalent to 100mg Enoxaparin sodium. Cardinex-40 : 4000 anti-Xa IU/0.4ml.
Cardinex is indicated for o Prophylaxis of venous thromboembolic disease (prevention of blood clot formation in the veins). Prevention of thrombus formation in the extracorporal circluation during haemodialysis.Treatment of unstable angina and non-Q-wave myocardial infarction during acute stage.Treatment of established deep vein thrombosis with or without pulmonary embolism.
Drug International Limited was incorporated under the Registrar of Joint Stock Companies in 1974 as a Private Limited Company. The company commenced formulation and production in 1983 and emerged as a pioneer in Bangladesh for adding a state of the art oral solid dosage plant. Since inception, Drug International Limited's primary objective has been to meet guidelines provided by major global regulatory bodies such as the World Health Organization Good Manufacturing Practices (WHO cGMP) guidelines.